DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Exploring the Pathogenic and Therapeutic Implications of Aberrant Splicing in Breast Cancer
Final rept. 1 Jul 2008-30 Jun 2011
SIR MORTIMER B DAVIS JEWISH GENERAL HOSPITAL MONTREAL (QUEBEC)
Pagination or Media Count:
In this proposal, we set out to a systematically monitor splicing variant profiles in breast cancer susceptibility genes and b explore the role of alternative splicing in breast chemotherapy using a global strategy. In doing so, we hope to identify and validate candidate splicing variants involved in tumorigenesis. Although the original the molecular barcode strategy was not implemented, we have made significant findings in two areas 1 we have identified over 1400 new splice variants and have shown that they are more prevalent in BRCA1-related breast cancer and 3 we have identified 3 novel fusion proteins. Perhaps most importantly, we have trained two young bioinformaticians, who both have bright futures in cancer research.
APPROVED FOR PUBLIC RELEASE